Overview

Price chart · mood · technical indicators

STOK

Stoke Therapeutics Incstock Healthcare

Biotechnology

$29.46170.77%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$10.64$40.22

Current: $29.46

Idea: EMA

1Y Return

+220.8%

Sharpe 3Y

0.93

Market Comparison

vs Healthcare Sector & Biotechnology Industry

STOK

+170.77%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—Forward 204.08

EPS (TTM)$-2.860.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$1.79BSmall cap

Wall Street coverage

$45.10median target· current $16.41 (+174.8%)12 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 204.08
PEG ratio: —
P/B: 4.81
P/S (TTM): 55.68
EV/EBITDA: 52.48

Profitability & growth

ROE (TTM): -45.6%
Operating margin: -858.0%
Revenue growth YoY: -96.1%
Dividend yield: —
Beta: 1.20

Last earnings

May 7, 2026 · Estimate $-0.82 · Reported $-0.79

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Stoke Therapeutics Inc

Company profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 45 WIGGINS AVENUE, BEDFORD, MA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$1.79B

Shares outstanding$62.3M

52W high$40.22

52W low$10.63

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

STOK

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan

Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti

The Bull Case For Stoke Therapeutics (STOK) Could Change Following Long-Term Zorevunersen Data And Phase 3 Plans

The Bull Case For Stoke Therapeutics (STOK) Could Change Following Long-Term Zorevunersen Data And Phase 3 Plans

Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics (Nasdaq:STOK) - Stock Analysis

Precision Trading with Stoke Therapeutics Inc. (STOK) Risk Zones

UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed

Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed

Zorevunersen tied to long-term benefits in Dravet syndrome

Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK)

Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK)

Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK)

Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK)

About Stoke Therapeutics Inc

Classification

Company profile

STOK

Market Comparison

STOK Market Analysis

Overview

STOK

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan

Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti

The Bull Case For Stoke Therapeutics (STOK) Could Change Following Long-Term Zorevunersen Data And Phase 3 Plans

The Bull Case For Stoke Therapeutics (STOK) Could Change Following Long-Term Zorevunersen Data And Phase 3 Plans

Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics (Nasdaq:STOK) - Stock Analysis

Precision Trading with Stoke Therapeutics Inc. (STOK) Risk Zones

UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed

Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed

Zorevunersen tied to long-term benefits in Dravet syndrome

Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK)

Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK)

Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK)

Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK)

About Stoke Therapeutics Inc

Classification

Company profile

STOK

Market Comparison